Karen L. Reckamp, MD, spoke about current other Lung-MAP and what her colleague can take away from the phase 2 substudy S1800A presented at 2022 ASCO.
At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Karen L. Reckamp, MD, director of the Division of Medical Oncology and professor of Medicine at Cedar-Sinai Medical Center, about ongoing studies that are part of the Lung-MAP master protocol. She also discussed major takeaways from the Lung-MAP nonmatched phase 2 substudy S1800A (NCT03971474) examining ramucirumab (Cyramza) plus pembrolizumab (Keytruda) vs standard of care in patients with advanced non–small cell lung cancer who were pretreated with immunotherapy and chemotherapy.
Lung-MAP has been a very important platform for studying targeted therapies and unmatched therapies for patients. Thus far, S1800A has been the main study that has been positive, and we’ve learned a lot. We have a KRAS study looking at co-mutations that is ongoing. We’ve learned a lot about how to design these trials and how to look forward. The new trials that are out there are exciting and should help to move the field forward.
We saw a survival benefit [of ramucirumab plus pembrolizumab in this population] and the curves separated early on from the very beginning. Thinking about nonchemotherapeutic regimens in tumors that have immunotherapy resistance, this is a regimen that is tolerated and potentially could be something used for patients and should be studied further. We need biomarkers to better select patients and understand the mechanisms of resistance to help us select the right therapies and be more precision-medicine based in the future.
Reckamp KL, Reman MW, Dragnev KH, et al . Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. J Clin Oncol. 2022;40(suppl 16):9004. doi:10.1200/JCO.2022.40.16_suppl.9004